Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b trial of continuous inhaled aztreonam in cystic fibrosis patients with chronic Burkholderia infection
2009-011740-19Phase 3
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and Burkholderiosis comparing Continuous AZLI with Placebo (2 arms).
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)Burkholderiosis
Beyond the preview
Go deeper on 2009-011740-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011740-19.